Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes

Abstract

In this study, we planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD). The patients were grouped according to the characteristics and the sites of metastases. Group I included 928 patients without metastasis. Group II, the OMBD group, included 68 patients. Group III, the widespread metastasis group, comprised 185 patients with multiple bone metastases and/or solid organ metastases. The mean overall survival of the groups was 16.7\u2009±\u20090.3 years in group 1, and 7.8\u2009±\u20090.8 and 5.9\u2009±\u20090.4 years in groups 2 and 3, respectively (p\u2009<\u20090.001 for the comparison of all three groups together; p\u2009<\u20090.001 for group 1 vs. 2 and 3) and (p\u2009=\u20090.037 for group 2 vs. group 3). In the subgroup survival analysis of patients in group 2 (OMBD), the mean and median survival was 5.5\u2009±\u20090.8 and 4.0\u2009±\u20090.8 years vs. 9.2\u2009±\u20090.98 and 9.0\u2009±\u20091.05 years in patients with more than one bone metastasis and single bone metastasis, respectively (p\u2009=\u20090.019). OMBD seems to be a different disease than breast cancer with isolated bone metastases. The high risk of developing OMBD, especially following locoregional recurrence, increases the importance of locoregional therapy in large T and N stage tumors.